Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8619-8626

  Zhu, Yongqiang ^a   Wu, Gang ^a   Zhu, Xinrong ^a   Ma, Yuheng ^a   Zhao, Xin ^a   Li, Yuejie ^a   Yuan, Yunxia ^a   Yang, Jie ^a   Yu, Sen ^a   Shao, Feng ^a   Lei, Meng ^b  

^a Jiangsu Key Laboratory of Molecular Targeted Antitumor Drug Research   (China)

^b NANJING FORESTRY UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (2 NAPHTHAMIDO) 3 (3 FLUOROPHENYL)PROPANAMIDO] 3 METHYLBUTYL BORONIC ACID; 1 [3 (3 FLUOROPHENYL) 3 (1,2,3,4 TETRAHYDRONAPHTHALENE 4 CARBOXAMIDO)PROPANAMIDO] 3 METHYLBUTYL BORONIC ACID; 1 [3 (3 FLUOROPHENYL) 3 (5,6,7,8 TETRAHYDRONAPHTHALENE 4 CARBOXAMIDO)PROPANAMIDO] 3 METHYLBUTYL BORONIC ACID; BETA AMINO ACID; BICYCLO COMPOUND; BORONIC ACID DERIVATIVE; BORTEZOMIB; DIPEPTIDE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; SOLID TUMOR; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; DIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650317245     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1009742     Document Type: Article

References (27)

1. Glickman, M. H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction Physiol. Rev. 2002, 82, 373-428
2. Hershko, A.; Ciechanover, A. The ubiquitin system Annu. Rev. Biochem. 1998, 67, 425-479
3. Pickart, C. M. Mechanisms underlying ubiquitination Annu. Rev. Biochem. 2001, 70, 503-533
4. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development Chem. Rev. 2007, 107, 687-717
5. Kisselev, A. F.; Akopian, T. N.; Castillo, V.; Goldberg, A. L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown Mol. Cell 1999, 4, 395-402
6. Adams, J. The development of proteasome inhibitors as anticancer drugs Cancer Cell 2004, 5, 417-421
7. Dispenzieri, A. Bortezomib for myeloma - Much ado about something N. Engl. J. Med. 2005, 352, 2546-2548
8. Cavo, M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma Leukemia 2006, 20, 1341-1352
9. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Yehuda, B. D.; Lonial, S.; Goldschmidt, M. B.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 2005, 352, 2487-2498
10. O'Connor, O. A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma Clin. Lymphoma Myeloma 2005, 6, 191-199
11. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J. Clin. Oncol. 2006, 24, 4867-4874
12. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 2003, 348, 2609-2617
13. Ludwig, H.; Khayat, D.; Giaccone, G.; Facon, T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer 2005, 104, 1794-1807
14. Zhu, Y. Q.; Zhao, X.; Zhu, X. R; Wu, G.; Li, Y. J.; Ma, Y. H.; Yuan, Y. X.; Yang, J.; Hu, Y.; Ai, L.; Gao, Q. Z. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: Comprehensive understanding of the SAR of α -amino acid boronates J. Med. Chem. 2009, 52, 4192-4199
15. Zhu, Y. Q.; Yao, S. Y; Xu, B.; Ge, Z. M.; Cui, J. R.; Chen, T. M.; Li, R. T. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors Bioorg. Med. Chem. 2009, 17, 6851-6861
16. Cardillo, G.; Tomasini, C. Asymmetric synthesis of β-amino acids and α-substituted β-amino acids Chem. Soc. Rev. 1996, 25, 117-128
17. Nicolaou, K. C.; Guy, R. K. The conquest of Taxol Angew. Chem., Int. Ed. Engl. 1995, 34, 2079-2090
18. Shinagawa, S.; Kanamaru, T.; Harada, S.; Asai, M.; Okazaki, H. Chemistry of emeriamine and its analogs and their inhibitory activity in long-chain fatty acid oxidation J. Med. Chem. 1987, 30, 1458-1463
19. Ford, P. W.; Gustafson, K. R.; McKee, T. C.; Shigematsu, N.; Maurizi, L. K.; Pannell, L. K.; Williams, D. E.; de Silva, E. D.; Lassota, P.; Allen, T. M.; Van Soest, R.; Andersen, R. J.; Boyd, M. R.; Papuamides, A-D HIV-inhibitory and cytotoxic depsipeptides from the sponge theonella mirabilis and theonella swinhoei collected in Papua new Guinea J. Am. Chem. Soc. 1999, 121, 5899-5909
20. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant Antitumor Agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J. Am. Chem. Soc. 1971, 93, 2325-2327
21. Roncari, G.; Kurylo-Borowska, Z.; Craig, L. C. On the chemical nature of the antibiotic edeine Biochemistry 1966, 5, 2153-2159
22. Gould, S. J.; Thiruvengadam, T. K. Studies of nitrogen metabolism using C-13 NMR spectroscopy. 3. Synthesis of DL-[3-13C, 2-15N]lysine and its incorporation into streptothricin F1 J. Am. Chem. Soc. 1981, 103, 6752-6754
23. Hinterman, T.; Seebach, D. The biological stability of β-peptides: No interactions between α- and β-peptidic structures? Chimia 1997, 51, 244-247
24. Zhu, Y. Q.; Zhu, X. R.; Wu, G.; Ma, Y. H.; Li, Y. J.; Zhao, X.; Yuan, Y. X.; Yang, J.; Yu, S.; Shao, F.; Li, R. T.; Ke, Y. R.; Lu, A. J.; Liu, Z. M.; Zhang, L. R. Synthesis, in vitro and in vivo biological evaluation, docking studies and structure-activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of β-amino acids J. Med. Chem. 2010, 53, 1990-1999
25. Klausner, Y. S.; Bodansky, M. Coupling reagents in peptide synthesis Synthesis 1972, 453-463
26. Pallombella, V. J.; Conner, E. M.; Fuseler, J. W.; Destree, A.; Davis, J. M.; Laroux, F. S.; Wolf, R. E.; Huang, J.; Brand, S.; Elliott, P. J.; Lazarus, D.; Parent, L.; Stein, R.; Adams, J.; Grisham, M. B. Role of the proteasome and NF-kappa B in streptoccal cell wall-induced polyarthritis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15671-15676
27. Teicher, B. A.; Ara, G.; Herbst, R.; Palombella, V. J.; Adams, J. The proteasome inhibitor PS-341 in cancer therapy Clin. Cancer Res. 1999, 5, 2638-2645